Journal
ONCOGENE
Volume 33, Issue 8, Pages 939-953Publisher
SPRINGERNATURE
DOI: 10.1038/onc.2013.80
Keywords
cancer; phosphatases; solid tumours
Funding
- National Institutes of Health Research
- Imperial Biomedical Research Centre
- Experimental Cancer Medicine Centre
- Breast Cancer Campaign
- Cancer Research UK
- Action Against Cancer
- Cancer Research UK [14549] Funding Source: researchfish
- National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish
Ask authors/readers for more resources
The relevance of potentially reversible post-translational modifications required for controlling cellular processes in cancer is one of the most thriving arenas of cellular and molecular biology. Any alteration in the balanced equilibrium between kinases and phosphatases may result in development and progression of various diseases, including different types of cancer, though phosphatases are relatively under-studied. Loss of phosphatases such as PTEN (phosphatase and tensin homologue deleted on chromosome 10), a known tumour suppressor, across tumour types lends credence to the development of phosphatidylinositol 3-kinase inhibitors alongside the use of phosphatase expression as a biomarker, though phase 3 trial data are lacking. In this review, we give an updated report on phosphatase dysregulation linked to organ-specific malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available